RLD strength for BE study [Design Issues]

posted by Brus – Spain, 2021-01-21 14:24 (109 d 17:26 ago) – Posting: # 22186
Views: 685

Dear Colleagues,

We are developing a generic of an RLD with two strengths (100 mg and 50 mg).

But viewing the dosage regimen of reference drug product, it would make sense to develop a 150 mg strength even though the reference product does not have it. So, our generic drug product will have 3 strengths (150, 100 and 50 mg).

What dose should the BE study be done with? (PK linearity has been demonstrated in the range of that doses).

Should RLD 100mg VS Generic 100mg be done or RLD 100mg + RLD 50mg VS generic 150mg?

Best regards,

Complete thread:

Activity
 Admin contact
21,446 posts in 4,483 threads, 1,511 registered users;
online 13 (0 registered, 13 guests [including 9 identified bots]).
Forum time: Tuesday 08:51 CEST (Europe/Vienna)

The fact that some geniuses were laughed at
does not imply that all who are laughed at are geniuses.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5